FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares


Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the FIT Biotech Oy and Bracknor Investment the Company's Board of Directors have resolved on December 28, 2017 to approve Bracknor's request relating to the funding programme to convert EUR 30,000 worth of Convertible Capital Notes into the Company's K shares. Due to the conversion of the Convertible Capital Notes, the Company transfers 2,100,840 K shares owned by the Company to Bracknor with the conversion price of EUR 0.01428 per share and the reserve for invested unrestricted equity of the Company will be increased by EUR 30,000.00.



from Biotech News